Argenx (ARGX) has secured the approval of the US Food and Drug Administration for a label expansion for Vyvgart and Vyvgart Hytrulo, extending the use to all serotypes of adult patients living with generalized myasthenia gravis, the company said late Friday.
The approval was supported by data from a phase 3 trial, which showed "rapid, significant and sustained improvements" in symptoms across serotypes, Argenx said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.